저온 멸균 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 장비별, 지역별, 부문별 예측(2025-2030년)

Low Temperature Sterilization Market Size, Share & Trends Analysis Report By Product (Ethylene Oxide Sterilizers, Hydrogen Peroxide Sterilizers), By Device (Endoscopes, Ophthalmology, Laparoscopic Kit), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,675,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,133,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,049,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

저온 멸균 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 저온 멸균 시장 규모는 2030년까지 50억 7,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 10.99%의 CAGR로 확대될 것으로 예상됩니다.

체온계, 내시경과 같은 의료기기를 효과적으로 살균하는 멸균기인 저온 멸균 솔루션은 HAI의 증가로 인해 향후 몇 년 동안 저온 멸균 솔루션에 대한 수요가 증가할 것으로 예상됩니다. 중저소득 국가에서는 15명, 고소득 국가에서는 7명이 입원 및 통원 기간 중 최소 한 번 이상 HAI를 경험한다고 합니다. 또한, 평균적으로 HAI에 걸린 환자 10명 중 1명은 사망할 가능성이 있습니다. 이러한 HAI의 증가로 인해 감염 관리와 예방에 대한 관심이 높아져 향후 저온살균법에 대한 수요가 더욱 증가할 것으로 예상됩니다.

기화식 과산화수소 살균의 인기가 높아짐에 따라 향후 몇 년 동안 시장 성장을 촉진할 것으로 예상됩니다. 이 살균 기술에 대한 정부의 지원적인 규정과 규제가 기화식 과산화수소 살균법을 사용하는 저온 멸균기에 대한 수요를 증가시킬 것으로 예상됩니다. 예를 들어, 2024년 1월 FDA는 저온 멸균 기술인 기화 과산화수소(VHP)를 의료기기 살균에 사용하도록 승인했습니다. 이 승인으로 FDA는 의료기기 산업에서 VHP를 멸균 기술로 광범위하게 채택할 수 있도록 촉진했습니다. 기화 과산화수소에 대한 규제 당국의 이러한 승인은 향후 몇 년 동안 시장 성장을 촉진할 것으로 예상됩니다.

기술의 발전으로 향후 몇 년 동안 시장이 성장할 것으로 예상됩니다. 예를 들어, 2024년 3월 Getinge는 열에 민감한 수술기구의 멸균을 위해 설계된 저온 멸균 시스템 'Poladus 150'을 발표했습니다. 이 시스템은 첨단 교차 오염 차단 기술을 갖추고 있어 HAII를 예방하는 데 도움이 됩니다. 또한, 라이프사이클 관리 도구인 FleetView 및 멸균 공급 관리 소프트웨어인 T-DOC와 호환됩니다. 업계에서 기술적으로 진보된 제품 출시와 함께 연결성 및 장비의 추적성이 향상됨에 따라 향후 시장 성장이 가속화될 것으로 예상됩니다.

저온 멸균 시장 보고서 하이라이트

• 에틸렌옥사이드 살균기는 기존의 고온 증기 살균이 불가능한 열과 습기에 민감한 의료기기를 광범위하고 효과적으로 살균할 수 있어 2024년 50.01% 이상의 점유율을 차지하며 제품 부문을 독차지했습니다.
• 과산화수소 살균기 부문은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 내시경은 이러한 장비에 크게 의존하는 최소침습 수술 및 진단 절차의 보급 증가로 인해 2024년 장비 유형 부문을 지배했습니다.
• 북미가 저온살균 시장을 독점한 것은 선진화된 의료 인프라, 엄격한 규제 체계, 병원 및 의료 시설의 감염 예방에 대한 수요 증가에 기인합니다.
• 저온 멸균 시장에 진출한 기업으로는 ASP Global(Fortive Corporation), Getinge, STERIS, Stryker, TDK Corporation, 3M, Steelco S.p.A., Bionics Scientific(a Unit of Kartal Projects Pvt. Ltd.), DE LAMA S.P.A., Genist Technocracy Pvt. of Kartal Projects Pvt Ltd.), DE LAMA S.P.A., Genist Technocracy Pvt. Qingdao Antech Scientific Co., Ltd., Renosem, Scitek Global Co., Ltd, SOLSTEO, Sterile Safequip And Chemicals LLP, Tuttnauer, HUMAN MEDITEK CO. MMM Group, Canon Singapore Pte.Ltd., INSTECH SYSTEMS, Biobase Biodusty(Shandong), Co., Ltd., Telstar(Azbil Group), Shinva Medical Instrument Co. 등이 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 저온 멸균 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 저온 멸균 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 저온 멸균 시장 : 부문 분석, 제품별, 2018-2030년(백만 달러)

• 저온 멸균 시장 : 제품 전망과 중요한 포인트
• 저온 멸균 시장 : 제품 변동 분석
• 제품별
• 에틸렌옥사이드 살균 장비
  • 에틸렌옥사이드 살균 장비 시장, 2018-2030년
  • 과산화수소 살균 장비
  • 기타

제5장 저온 멸균 시장 : 부문 분석, 장비별, 2018-2030년(백만 달러)

• 저온 멸균 시장 : 장비 전망과 중요한 포인트
• 저온 멸균 시장 : 장비 변동 분석
• 장비 유형별
• 내시경
  • 내시경 시장, 2018-2030년
  • 연성 내시경
  • 경성 내시경
• 복강경 키트
  • 복강경 검사 키트 시장, 2018-2030년
• 안과
  • 안과 시장, 2018-2030년
• 이비인후과(ORL)
  • 이비인후과(ORL) 시장, 2018-2030년
• 기타 기기
  • 기타 기기 시장, 2018-2030년

제6장 저온 멸균 시장 : 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 시장 진출 기업 분류
• 최근 동향과 영향 분석, 주요 시장 진출 기업별
• 기업 시장 점유율 분석, 2024년
• 주요 기업 개요
  • ASP Global(Fortive Corporation)
  • Getinge
  • STERIS
  • Stryker
  • TDK Corporation
  • 3M
  • Steelco S.p.A.
  • Bionics Scientific(a Unit of Kartal Projects Pvt Ltd.)
  • E LAMA S.P.A.
  • Genist Technocracy Pvt. Ltd.
  • Andersen Sterilizers
  • Labotronics Scientific
  • Labtron Equipment Ltd
  • Qingdao Antech Scientific Co., Ltd.
  • Renosem
  • Scitek Global Co., Ltd.
  • SOLSTEO
  • Sterile Safequip And Chemicals Llp
  • Tuttnauer
  • HUMAN MEDITEK CO., LTD.
  • MMM Group
  • Canon Singapore Pte. Ltd.
  • INSTECH SYSTEMS
  • Biobase Biodusty(Shandong), Co., Ltd.
  • Telstar(Azbil Group)
  • Shinva Medical Instrument Co., Ltd.

ksm

영문 목차

영문목차

Low Temperature Sterilization Market Growth & Trends:

The global low temperature sterilization market size is anticipated to reach USD 5.07 billion by 2030 and is anticipated to expand at a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of HAIs is expected to drive demand for low-temperature sterilization solutions in the coming years, as these sterilizers effectively sanitize medical instruments like thermometers and endoscopes. According to data published by the WHO in May 2022, out of every 100 patients in acute-care healthcare settings such as hospitals, 15 in low- and middle-income nations and 7 in high-income countries will develop at least one HAI during their hospital visit and stay. Furthermore, on average, 1 in 10 patients affected by HAI may die. This increasing prevalence of HAIs is expected to increase the focus on infection control and prevention, further boosting the future demand for low-temperature sterilization methods.

The increasing popularity of vaporized hydrogen peroxide sterilization is anticipated to boost market growth in the coming years. Supportive government rules and regulations for this sterilization technique are expected to boost the demand for low-temperature sterilizers that use vaporized hydrogen peroxide sterilization methods. For instance, in January 2024, Vaporized Hydrogen Peroxide (VHP), a low-temperature sterilization technique, was approved by the FDA to sterilize medical devices. With this authorization, the agency facilitated broader adoption of VHP as a sterilization technique for the medical device industry. Such approvals from the regulatory authorities for vaporized hydrogen peroxide are anticipated to boost the market growth in the coming years.

The market is expected to grow in the coming years due to technological advancements. For instance, in March 2024, Getinge introduced a low-temperature sterilization system called Poladus 150, designed for sterilizing heat-sensitive surgical instruments. This system features advanced cross-contamination barrier technology and helps prevent HAII. Moreover, it is compatible with FleetView, a lifecycle management tool, and T-DOC, a sterile supply management software. The increasing connectivity and instrument traceability, along with the launch of technologically advanced products by industry players, are anticipated to drive market growth in the future.

Low Temperature Sterilization Market Report Highlights:

• Ethylene oxide sterilizers dominated the product segment with more than 50.01% share in 2024 owing to their ability to effectively sterilize a wide range of heat- and moisture-sensitive medical devices that cannot withstand traditional high-temperature steam sterilization.
• The hydrogen peroxide sterilizers segment is expected to grow at the fastest CAGR over the forecast period.
• The endoscopes dominated the device type segment in 2024 owing to their increasing prevalence of minimally invasive surgeries and diagnostic procedures, which rely heavily on these instruments.
• North America dominated the low temperature sterilization market owing to the advanced healthcare infrastructure, stringent regulatory frameworks, and the growing demand for infection control measures in hospitals & healthcare facilities.
• Market players operating in low temperature sterilization market include ASP Global (Fortive Corporation), Getinge, STERIS, Stryker, TDK Corporation, 3M, Steelco S.p.A., Bionics Scientific (a Unit of Kartal Projects Pvt Ltd.), DE LAMA S.P.A., Genist Technocracy Pvt. Ltd., Andersen Sterilizers, Labotronics Scientific, Labtron Equipment Ltd, Qingdao Antech Scientific Co., Ltd., Renosem, Scitek Global Co., Ltd., SOLSTEO, Sterile Safequip And Chemicals LLP, Tuttnauer, HUMAN MEDITEK CO., LTD., MMM Group, Canon Singapore Pte. Ltd., INSTECH SYSTEMS, Biobase Biodusty (Shandong), Co., Ltd., Telstar (Azbil Group), Shinva Medical Instrument Co., Ltd.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Device
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Low Temperature Sterilization Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Developments in Medical Devices
    • 3.2.1.2. Increasing Investment for Sterilization Devices and Infrastructure
    • 3.2.1.3. Expansion Into Emerging Economies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Risks and Complications Associated With Different Sterilization Methods
• 3.3. Low Temperature Sterilization Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Low Temperature Sterilization Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1. Low Temperature Sterilization Market: Product Outlook and Key Takeaways
• 4.2. Low Temperature Sterilization Market: Product Movement Analysis
• 4.3. Low Temperature Sterilization Market Estimates & Forecast, by Product (USD Million)
• 4.4. Ethylene Oxide Sterilizers
  • 4.4.1. Ethylene Oxide Sterilizers Market, 2018 - 2030 (USD Million)
  • 4.4.2. Hydrogen Peroxide Sterilizers
    • 4.4.2.1. Hydrogen Peroxide Sterilizers Market, 2018 - 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Low Temperature Sterilization Market - Segment Analysis, by Device, 2018 - 2030 (USD Million)

• 5.1. Low Temperature Sterilization Market: Device Outlook and Key Takeaways
• 5.2. Low Temperature Sterilization Market: Device Movement Analysis
• 5.3. Low Temperature Sterilization Market Estimates & Forecast, by Device Type (USD Million)
• 5.4. Endoscopes
  • 5.4.1. Endoscopes Market, 2018 - 2030 (USD Million)
  • 5.4.2. Flexible Endoscopes
    • 5.4.2.1. Flexible Endoscopes Market, 2018 - 2030 (USD Million)
    • 5.4.2.2. Single-Channel Flexible Endoscopes
      • 5.4.2.2.1. Single-Channel Flexible Endoscopes Market, 2018 - 2030 (USD Million)
    • 5.4.2.3. Dual-Channel Flexible Endoscopes
      • 5.4.2.3.1. Dual-Channel Flexible Endoscopes Market, 2018 - 2030 (USD Million)
    • 5.4.2.4. Triple-Channel Flexible Endoscopes
      • 5.4.2.4.1. Triple-Channel Flexible Endoscopes Market, 2018 - 2030 (USD Million)
  • 5.4.3. Rigid Endoscopes
    • 5.4.3.1. Rigid Endoscopes Market, 2018 - 2030 (USD Million)
    • 5.4.3.2. Single-Channel Rigid Endoscopes
      • 5.4.3.2.1. Single-Channel Rigid Endoscopes Market, 2018 - 2030 (USD Million)
    • 5.4.3.3. Dual-Channel Rigid Endoscopes
      • 5.4.3.3.1. Dual-Channel Rigid Endoscopes Market, 2018 - 2030 (USD Million)
• 5.5. Laparoscopy Kit
  • 5.5.1. Laparoscopy Kit Market, 2018 - 2030 (USD Million)
• 5.6. Ophthalmology
  • 5.6.1. Ophthalmology Market, 2018 - 2030 (USD Million)
• 5.7. Otolaryngology (ORL)
  • 5.7.1. Otolaryngology (ORL) Market, 2018 - 2030 (USD Million)
• 5.8. Other Instruments
  • 5.8.1. Other Instruments Market, 2018 - 2030 (USD Million)

Chapter 6. Low Temperature Sterilization Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Key Company Profiles
  • 7.4.1. ASP Global (Fortive Corporation)
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Getinge
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. STERIS
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Stryker
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. TDK Corporation
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. 3M
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Steelco S.p.A.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Bionics Scientific (a Unit of Kartal Projects Pvt Ltd.)
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. DE LAMA S.P.A.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Genist Technocracy Pvt. Ltd.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Andersen Sterilizers
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Labotronics Scientific
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. Labtron Equipment Ltd
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Qingdao Antech Scientific Co., Ltd.
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. Renosem
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Product benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Scitek Global Co., Ltd.
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Product benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. SOLSTEO
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Product benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Sterile Safequip And Chemicals Llp
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Product benchmarking
    • 7.4.18.4. Strategic initiatives
  • 7.4.19. Tuttnauer
    • 7.4.19.1. Company overview
    • 7.4.19.2. Financial performance
    • 7.4.19.3. Product benchmarking
    • 7.4.19.4. Strategic initiatives
  • 7.4.20. HUMAN MEDITEK CO., LTD.
    • 7.4.20.1. Company overview
    • 7.4.20.2. Financial performance
    • 7.4.20.3. Product benchmarking
    • 7.4.20.4. Strategic initiatives
  • 7.4.21. MMM Group
    • 7.4.21.1. Company overview
    • 7.4.21.2. Financial performance
    • 7.4.21.3. Product benchmarking
    • 7.4.21.4. Strategic initiatives
  • 7.4.22. Canon Singapore Pte. Ltd.
    • 7.4.22.1. Company overview
    • 7.4.22.2. Financial performance
    • 7.4.22.3. Product benchmarking
    • 7.4.22.4. Strategic initiatives
  • 7.4.23. INSTECH SYSTEMS
    • 7.4.23.1. Company overview
    • 7.4.23.2. Financial performance
    • 7.4.23.3. Product benchmarking
    • 7.4.23.4. Strategic initiatives
  • 7.4.24. Biobase Biodusty (Shandong), Co., Ltd.
    • 7.4.24.1. Company overview
    • 7.4.24.2. Financial performance
    • 7.4.24.3. Product benchmarking
    • 7.4.24.4. Strategic initiatives
  • 7.4.25. Telstar (Azbil Group)
    • 7.4.25.1. Company overview
    • 7.4.25.2. Financial performance
    • 7.4.25.3. Product benchmarking
    • 7.4.25.4. Strategic initiatives
  • 7.4.26. Shinva Medical Instrument Co., Ltd.
    • 7.4.26.1. Company overview
    • 7.4.26.2. Financial performance
    • 7.4.26.3. Product benchmarking
    • 7.4.26.4. Strategic initiatives

관련자료